ArticleExperimental and therapeutic medicine2019
Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Tigecycline Induced Hemorrhagic Vesiculobullous Leukocytoclastic Vasculitis: A Rare Clinical Presentation.Oman medical journal · 2026Article
- Rare skin adverse reactions induced by osimertinib: a case report and literature review.Frontiers in oncology · 2025Article
- Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment-Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives.Life (Basel, Switzerland) · 2024Article
- Retrospective clinical study analysis of skin adverse reactions related to epidermal growth factor receptor inhibitors.Translational cancer research · 2024Article
- Blood culture-negative infective endocarditis presenting with atypical dermatologic manifestation: A rare case report and review of the literature.Clinical case reports · 2023Article
- A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma.CEN case reports · 2023Article
- Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature.JTO clinical and research reports · 2022Article
- Vasculitis associated with the use of an intrauterine device: A case report.Experimental and therapeutic medicine · 2021Article
- Article
- Gadolinium-based contrast agents in neurofibromatosis type 1 (Review).Experimental and therapeutic medicine · 2021Review
- Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report.Medicines (Basel, Switzerland) · 2021Article
- Acyclovir-induced immune thrombocytopenia: Case report and review of the literature.Experimental and therapeutic medicine · 2020Article
- Influence of phytochemicals in induced psoriasis (Review).Experimental and therapeutic medicine · 2020Review
- FOXP3 in Melanoma with Regression: Between Tumoral Expression and Regulatory T Cell Upregulation.Journal of immunology research · 2020Review
- The Second Conference of the Romanian Society of Immuno-Dermatology, Bucharest, September 27-29, 2018.Experimental and therapeutic medicine · 2019Article
- Leukocytoclastic Vasculitic Rash Following Second Dose of Moderna COVID-19 Vaccine.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erlotinib is a targeted anticancer therapy used for treating epidermal growth factor receptor (EGFR) mutation positive lung cancer in advanced stage as well as for other malignancies. The most common cutaneous side effect of erlotinib, are well documented; however the number of reports regarding cutaneous leukocytoclastic vasculitis (CLCV) are limited. We report a case, a 58-year-old, 60 kg weight, non-smoking woman suffering of lung adenocarcinoma and brain metastases treated with erlotinib monotherapy with 150 mg/day dose, who presents cutaneous leukocytoclastic vasculitis after 8 months of initiating the treatment. The administration of the drug was discontinued and oral prednisolone treatment was introduced at 1 mg/kg body weight dose for two weeks, decreasing the dose with 5 mg, at every 3 days. The treatment was combined with topical potent steroid and antibiotic therapy used once, daily. The lesions cleared within 7 weeks without recurrence. The treatment with erlotinib was restarted after 14 days with a lower dose of 100 mg/day. The skin lesions have not occurred anymore. Unfortunately the evolution was unfavorable, our patient died 3 months after the vasculitis healing, due to the complications of new metastases that occurred. This may indicate the inefficiency of erlotinib. The late onset of 240 days of the vasculitis and the presumed inefficiency of the drug lead to the speculation that the appearance of cutaneous vasculitis could be a worsening clinical marker of the tumor response. This limited number of cases precludes any meaningful interpretation of data about the erlotinib induced cutaneous vasculitis. Further investigations are needed to assess cutaneous vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.